Akebia Therapeutics (AKBA) Stock Forecast, Price Target & Predictions
AKBA Stock Forecast
Akebia Therapeutics stock forecast is as follows: an average price target of $6.50 (represents a 345.21% upside from AKBA’s last price of $1.46) and a rating consensus of 'Buy', based on 5 wall street analysts offering a 1-year stock forecast.
AKBA Price Target
The average price target for Akebia Therapeutics (AKBA) is $6.50 based on 1-year price targets from 5 Wall Street analysts in the past 3 months, with a price target range of $7.00 to $6.00. This represents a potential 345.21% upside from AKBA's last price of $1.46.
AKBA Analyst Ratings
According to 5 Wall Street analysts, Akebia Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for AKBA stock is 0 'Strong Buy' (0.00%), 4 'Buy' (80.00%), 1 'Hold' (20.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Akebia Therapeutics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Mar 28, 2024 | Ed Arce | H.C. Wainwright | $6.00 | $1.98 | 203.03% | 310.96% |
| Mar 03, 2022 | Serge Belanger | Needham | $7.00 | $2.65 | 164.15% | 379.45% |
The latest Akebia Therapeutics stock forecast, released on Mar 28, 2024 by Ed Arce from H.C. Wainwright, set a price target of $6.00, which represents a 203.03% increase from the stock price at the time of the forecast ($1.98), and a 310.96% increase from AKBA last price ($1.46).
Akebia Therapeutics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 1 |
| Avg Price Target | - | - | $6.00 |
| Last Closing Price | $1.46 | $1.46 | $1.46 |
| Upside/Downside | -100.00% | -100.00% | 310.96% |
In the current month, the average price target of Akebia Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Akebia Therapeutics's last price of $1.46. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Sep 06, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Aug 12, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Mar 28, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| May 31, 2023 | Seaport Global | - | Sector Weight | Downgrade |
| May 31, 2023 | Piper Sandler | - | Overweight | Upgrade |
| Mar 03, 2022 | Needham | Buy | Buy | Hold |
| Apr 29, 2021 | Mizuho Securities | Buy | Buy | Hold |
Akebia Therapeutics's last stock rating was published by H.C. Wainwright on Sep 06, 2024. The company gave AKBA a "Buy" rating, the same as its previous rate.
Akebia Therapeutics Financial Forecast
Akebia Therapeutics Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Sep 18 | Jun 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | $42.05M | $56.38M | $40.13M | $55.18M | $48.96M | - | $61.70M | $59.60M | $48.76M | $52.91M | $52.30M | $56.70M | $59.99M | $90.14M | $88.48M | $69.56M | $91.98M | $100.80M | $72.67M | $53.17M | $48.79M |
| Avg Forecast | $55.37M | $45.93M | $38.53M | $37.77M | $51.23M | $44.50M | $49.80M | $46.09M | $55.39M | $48.18M | $59.10M | $46.68M | $47.40M | $48.88M | $53.03M | $44.27M | $51.77M | $49.62M | $52.31M | $42.32M | $51.10M | $84.90M | $74.18M | $77.48M | $93.15M | $99.38M | $91.12M | $81.02M | $74.02M | $41.48M |
| High Forecast | $57.00M | $47.29M | $39.67M | $38.88M | $52.74M | $44.66M | $51.27M | $47.44M | $56.06M | $49.60M | $60.84M | $48.06M | $48.79M | $50.32M | $53.03M | $47.35M | $55.38M | $53.08M | $55.95M | $45.27M | $54.66M | $90.82M | $79.35M | $82.88M | $99.64M | $106.30M | $97.47M | $86.66M | $88.82M | $49.78M |
| Low Forecast | $52.49M | $43.55M | $36.53M | $35.81M | $48.57M | $44.34M | $47.22M | $43.69M | $54.73M | $45.68M | $56.03M | $44.26M | $44.94M | $46.34M | $53.03M | $41.81M | $48.89M | $46.86M | $49.40M | $39.97M | $48.26M | $80.18M | $70.06M | $73.17M | $87.97M | $93.85M | $86.05M | $76.51M | $59.21M | $33.18M |
| # Analysts | - | - | - | - | 1 | 2 | 1 | 1 | 2 | 1 | 1 | 1 | - | - | - | - | 1 | 1 | 1 | 4 | 6 | 4 | 6 | 4 | 5 | 3 | 5 | 3 | 8 | 15 |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.87% | 0.95% | 0.86% | 1.16% | 1.00% | - | 1.39% | 1.15% | 0.98% | 1.01% | 1.24% | 1.11% | 0.71% | 1.22% | 1.14% | 0.75% | 0.93% | 1.11% | 0.90% | 0.72% | 1.18% |
Akebia Therapeutics's average Quarter revenue forecast for Dec 23 based on 2 analysts is $55.39M, with a low forecast of $54.73M, and a high forecast of $56.06M. AKBA's average Quarter revenue forecast represents a 31.74% increase compared to the company's last Quarter revenue of $42.05M (Sep 23).
Akebia Therapeutics EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Sep 18 | Jun 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | 1 | 2 | 1 | 1 | 2 | 1 | 1 | 1 | - | - | - | - | 1 | 1 | 1 | 4 | 6 | 4 | 6 | 4 | 5 | 3 | 5 | 3 | 8 | 15 |
| EBITDA | - | - | - | - | - | - | - | - | - | $-3.50M | $-8.66M | $-24.73M | $-3.91M | $-37.40M | - | $-47.93M | $-66.31M | $-44.98M | $-68.57M | $-55.25M | $-81.59M | $-51.06M | $-163.82M | $-49.15M | $-87.34M | $-45.90M | $-48.84M | $-64.77M | $-24.04M | $-32.29M |
| Avg Forecast | $-33.60M | $-27.88M | $-23.39M | $-22.92M | $-31.10M | $-27.01M | $-30.23M | $-46.00M | $-33.62M | $-29.24M | $-35.87M | $-41.82M | $-28.77M | $-46.38M | $-32.19M | $-38.01M | $-31.42M | $-42.16M | $-44.79M | $-27.24M | $-43.60M | $-26.43M | $-100.91M | $-63.49M | $-56.54M | $-42.91M | $-25.43M | $-32.49M | $-33.08M | $-27.88M |
| High Forecast | $-31.86M | $-26.43M | $-22.17M | $-21.73M | $-29.48M | $-26.91M | $-28.66M | $-36.80M | $-33.22M | $-27.73M | $-34.01M | $-33.45M | $-27.28M | $-37.10M | $-32.19M | $-30.41M | $-29.67M | $-33.73M | $-35.83M | $-21.80M | $-34.88M | $-21.15M | $-80.73M | $-50.79M | $-53.39M | $-34.33M | $-20.35M | $-25.99M | $-26.47M | $-22.30M |
| Low Forecast | $-34.59M | $-28.70M | $-24.08M | $-23.60M | $-32.01M | $-27.10M | $-31.12M | $-55.20M | $-34.03M | $-30.10M | $-36.93M | $-50.18M | $-29.62M | $-55.66M | $-32.19M | $-45.62M | $-33.61M | $-50.60M | $-53.75M | $-32.69M | $-52.32M | $-31.72M | $-121.10M | $-76.19M | $-60.47M | $-51.49M | $-30.52M | $-38.99M | $-39.70M | $-33.46M |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.12% | 0.24% | 0.59% | 0.14% | 0.81% | - | 1.26% | 2.11% | 1.07% | 1.53% | 2.03% | 1.87% | 1.93% | 1.62% | 0.77% | 1.54% | 1.07% | 1.92% | 1.99% | 0.73% | 1.16% |
undefined analysts predict AKBA's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Akebia Therapeutics's previous annual EBITDA (undefined) of $NaN.
Akebia Therapeutics Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Sep 18 | Jun 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | 1 | 2 | 1 | 1 | 2 | 1 | 1 | 1 | - | - | - | - | 1 | 1 | 1 | 4 | 6 | 4 | 6 | 4 | 5 | 3 | 5 | 3 | 8 | 15 |
| Net Income | - | - | - | - | - | - | - | - | - | $-14.49M | $-11.17M | $-16.74M | $-8.76M | $-55.74M | - | $-66.35M | $-65.59M | $-59.54M | $-83.04M | $-69.58M | $-87.00M | $-59.96M | $-175.75M | $-60.75M | $-94.48M | $-54.59M | $-58.17M | $-72.42M | $-26.05M | $-34.07M |
| Avg Forecast | $-6.99M | $-11.88M | $-18.87M | $-16.78M | $-11.18M | $-13.28M | $-15.15M | $-59.90M | $-8.04M | $-17.82M | $-5.24M | $-54.46M | $-38.45M | $-61.40M | $-66.27M | $-49.51M | $-58.10M | $-55.82M | $-54.24M | $-34.31M | $-47.85M | $-31.04M | $-108.26M | $-75.44M | $-90.01M | $-50.78M | $-29.99M | $-35.85M | $-33.37M | $-28.06M |
| High Forecast | $-6.52M | $-11.08M | $-17.60M | $-15.64M | $-10.43M | $-7.97M | $-14.13M | $-47.92M | $-4.82M | $-16.62M | $-4.89M | $-43.57M | $-35.85M | $-49.12M | $-66.27M | $-39.61M | $-53.90M | $-44.66M | $-43.39M | $-27.45M | $-38.28M | $-24.83M | $-86.61M | $-60.36M | $-83.50M | $-40.62M | $-24.00M | $-28.68M | $-26.70M | $-22.45M |
| Low Forecast | $-7.26M | $-12.34M | $-19.60M | $-17.42M | $-11.61M | $-15.94M | $-15.73M | $-71.88M | $-9.65M | $-18.51M | $-5.44M | $-65.35M | $-39.92M | $-73.69M | $-66.27M | $-59.41M | $-63.36M | $-66.99M | $-65.09M | $-41.17M | $-57.42M | $-37.25M | $-129.92M | $-90.53M | $-98.16M | $-60.93M | $-35.99M | $-43.02M | $-40.05M | $-33.67M |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.81% | 2.13% | 0.31% | 0.23% | 0.91% | - | 1.34% | 1.13% | 1.07% | 1.53% | 2.03% | 1.82% | 1.93% | 1.62% | 0.81% | 1.05% | 1.08% | 1.94% | 2.02% | 0.78% | 1.21% |
Akebia Therapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. AKBA's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Akebia Therapeutics SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Sep 18 | Jun 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | 1 | 2 | 1 | 1 | 2 | 1 | 1 | 1 | - | - | - | - | 1 | 1 | 1 | 4 | 6 | 4 | 6 | 4 | 5 | 3 | 5 | 3 | 8 | 15 |
| SG&A | - | - | - | - | - | - | - | - | - | $22.71M | $27.04M | $25.22M | $31.50M | $31.66M | - | $45.02M | $45.85M | $47.23M | $42.55M | $42.02M | $41.29M | $40.88M | $36.53M | $38.66M | $45.89M | $35.11M | $36.96M | $35.03M | $10.38M | $12.54M |
| Avg Forecast | $31.00M | $25.72M | $21.57M | $21.14M | $28.68M | $24.91M | $27.88M | $43.20M | $31.01M | $26.98M | $33.09M | $39.27M | $26.54M | $48.70M | $29.69M | $35.70M | $28.98M | $44.28M | $27.79M | $20.72M | $22.71M | $21.16M | $22.50M | $48.01M | $52.15M | $32.66M | $19.06M | $17.34M | $13.30M | $10.33M |
| High Forecast | $31.91M | $26.47M | $22.21M | $21.77M | $29.53M | $25.00M | $28.70M | $51.84M | $31.39M | $27.77M | $34.06M | $47.13M | $27.32M | $58.44M | $29.69M | $42.84M | $31.00M | $53.13M | $33.35M | $24.87M | $27.25M | $25.39M | $27.00M | $57.61M | $55.79M | $39.19M | $22.87M | $20.81M | $15.96M | $12.39M |
| Low Forecast | $29.39M | $24.38M | $20.45M | $20.05M | $27.20M | $24.83M | $26.44M | $34.56M | $30.64M | $25.58M | $31.37M | $31.42M | $25.16M | $38.96M | $29.69M | $28.56M | $27.37M | $35.42M | $22.23M | $16.58M | $18.17M | $16.93M | $18.00M | $38.41M | $49.25M | $26.13M | $15.25M | $13.87M | $10.64M | $8.26M |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.84% | 0.82% | 0.64% | 1.19% | 0.65% | - | 1.26% | 1.58% | 1.07% | 1.53% | 2.03% | 1.82% | 1.93% | 1.62% | 0.81% | 0.88% | 1.08% | 1.94% | 2.02% | 0.78% | 1.21% |
Akebia Therapeutics's average Quarter SG&A projection for Dec 23 is $31.01M, based on 2 Wall Street analysts, with a range of $30.64M to $31.39M. The forecast indicates a 36.56% rise compared to AKBA last annual SG&A of $22.71M (Sep 23).
Akebia Therapeutics EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Sep 18 | Jun 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | 1 | 2 | 1 | 1 | 2 | 1 | 1 | 1 | - | - | - | - | 1 | 1 | 1 | 4 | 6 | 4 | 6 | 4 | 5 | 3 | 5 | 3 | 8 | 15 |
| EPS | - | - | - | - | - | - | - | - | - | $-0.08 | $-0.06 | $-0.09 | $-0.05 | $-0.30 | - | $-0.37 | $-0.37 | $-0.34 | $-0.51 | $-0.45 | $-0.60 | $-0.42 | $-1.28 | $-0.47 | $-0.79 | $-0.46 | $-0.49 | $-0.62 | $-0.46 | $-0.60 |
| Avg Forecast | $-0.03 | $-0.06 | $-0.09 | $-0.08 | $-0.05 | $-0.06 | $-0.07 | $-0.07 | $-0.04 | $-0.09 | $-0.03 | $-0.14 | $-0.18 | $-0.17 | $-0.32 | $-0.29 | $-0.30 | $-0.32 | $-0.34 | $-0.37 | $-0.40 | $-0.17 | $-0.48 | $-0.62 | $-0.47 | $-0.43 | $-0.32 | $-0.40 | $-0.82 | $-0.42 |
| High Forecast | $-0.03 | $-0.05 | $-0.08 | $-0.07 | $-0.05 | $-0.04 | $-0.07 | $-0.07 | $-0.02 | $-0.08 | $-0.02 | $-0.14 | $-0.17 | $-0.16 | $-0.32 | $-0.27 | $-0.28 | $-0.30 | $-0.31 | $-0.34 | $-0.37 | $-0.16 | $-0.45 | $-0.57 | $-0.44 | $-0.39 | $-0.30 | $-0.37 | $-0.66 | $-0.34 |
| Low Forecast | $-0.03 | $-0.06 | $-0.09 | $-0.08 | $-0.06 | $-0.08 | $-0.08 | $-0.07 | $-0.05 | $-0.09 | $-0.03 | $-0.15 | $-0.19 | $-0.18 | $-0.32 | $-0.31 | $-0.33 | $-0.35 | $-0.37 | $-0.40 | $-0.43 | $-0.18 | $-0.52 | $-0.67 | $-0.52 | $-0.46 | $-0.35 | $-0.44 | $-0.98 | $-0.50 |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.90% | 2.39% | 0.62% | 0.26% | 1.76% | - | 1.29% | 1.21% | 1.06% | 1.50% | 1.22% | 1.51% | 2.49% | 2.67% | 0.76% | 1.67% | 1.08% | 1.53% | 1.55% | 0.56% | 1.43% |
According to undefined Wall Street analysts, Akebia Therapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to AKBA previous annual EPS of $NaN (undefined).
Akebia Therapeutics Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| HEPA | Hepion Pharmaceuticals | $0.74 | $70.00 | 9359.46% | Buy |
| ELEV | Elevation Oncology | $0.61 | $9.00 | 1375.41% | Buy |
| XFOR | X4 Pharmaceuticals | $0.71 | $3.67 | 416.90% | Buy |
| AKBA | Akebia Therapeutics | $1.46 | $6.50 | 345.21% | Buy |
| CDTX | Cidara Therapeutics | $11.94 | $24.00 | 101.01% | Buy |
| MCRB | Seres Therapeutics | $1.00 | $1.25 | 25.00% | Buy |
AKBA Forecast FAQ
Is Akebia Therapeutics a good buy?
Yes, according to 5 Wall Street analysts, Akebia Therapeutics (AKBA) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 4 'Buy' recommendations, accounting for 80.00% of AKBA's total ratings.
What is AKBA's price target?
Akebia Therapeutics (AKBA) average price target is $6.5 with a range of $6 to $7, implying a 345.21% from its last price of $1.46. The data is based on 5 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Akebia Therapeutics stock go up soon?
According to Wall Street analysts' prediction for AKBA stock, the company can go up by 345.21% (from the last price of $1.46 to the average price target of $6.5), up by 379.45% based on the highest stock price target, and up by 310.96% based on the lowest stock price target.
Can Akebia Therapeutics stock reach $2?
AKBA's average twelve months analyst stock price target of $6.5 supports the claim that Akebia Therapeutics can reach $2 in the near future.
What are Akebia Therapeutics's analysts' financial forecasts?
Akebia Therapeutics's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $191.62M (high $196.11M, low $183.83M), average EBITDA is $-134M (high $-122M, low $-145M), average net income is $-99.519M (high $-80.45M, low $-115M), average SG&A $124.68M (high $135.07M, low $113.02M), and average EPS is $-0.261 (high $-0.222, low $-0.281). AKBA's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $177.6M (high $182.83M, low $168.38M), average EBITDA is $-108M (high $-102M, low $-111M), average net income is $-54.523M (high $-50.845M, low $-56.61M), average SG&A $99.43M (high $102.36M, low $94.27M), and average EPS is $-0.26 (high $-0.242, low $-0.27).
Did the AKBA's actual financial results beat the analysts' financial forecasts?
Based on Akebia Therapeutics's last annual report (Dec 2023), the company's revenue was $194.62M, which missed the average analysts forecast of $209.36M by -7.04%. Apple's EBITDA was $-46.256M, missing the average prediction of $-141M by -67.09%. The company's net income was $-51.925M, missing the average estimation of $-85.563M by -39.31%. Apple's SG&A was $100.23M, missing the average forecast of $130.35M by -23.11%. Lastly, the company's EPS was $-0.0003, missing the average prediction of $-0.293 by -99.90%. In terms of the last quarterly report (Sep 2023), Akebia Therapeutics's revenue was $42.05M, missing the average analysts' forecast of $48.18M by -12.74%. The company's EBITDA was $-3.503M, missing the average prediction of $-29.244M by -88.02%. Akebia Therapeutics's net income was $-14.489M, missing the average estimation of $-17.825M by -18.72%. The company's SG&A was $22.71M, missing the average forecast of $26.98M by -15.82%. Lastly, the company's EPS was $-0.0769, missing the average prediction of $-0.085 by -9.53%